重视肝炎病毒性肝细胞癌患者的抗病毒治疗

Gastroenterology & Endoscopy Pub Date : 2023-01-01 DOI:10.1016/j.gande.2022.10.001

Shuling Wu , Liu Yang , Xiaoyue Bi , Yanjie Lin , Wen Deng , Tingting Jiang , Minghui Li , Yao Xie

{"title":"重视肝炎病毒性肝细胞癌患者的抗病毒治疗","authors":"Shuling Wu , Liu Yang , Xiaoyue Bi , Yanjie Lin , Wen Deng , Tingting Jiang , Minghui Li , Yao Xie","doi":"10.1016/j.gande.2022.10.001","DOIUrl":null,"url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide that seriously threatens human health. Chronic infection of hepatitis virus B, C and D is closely related to the occurrence of HCC, about 80% HCC cases are caused by chronic viral hepatitis. Effective antiviral therapy can control liver inflammation, reduce the occurrence of HCC and reduce the recurrence of HCC after surgery treatment. In addition, during chemotherapy such as transarterial chemoembolization (TACE) or hepatic artery infusion chemotherapy (HAIC), targeted therapy and immunotherapy for HCC, antiviral therapy is also needed to prevent hepatitis virus reactivation. Therefore, antiviral therapy plays an important role in the prevention and treatment of HCC.</p></div>","PeriodicalId":100571,"journal":{"name":"Gastroenterology & Endoscopy","volume":"1 1","pages":"Pages 5-10"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus\",\"authors\":\"Shuling Wu , Liu Yang , Xiaoyue Bi , Yanjie Lin , Wen Deng , Tingting Jiang , Minghui Li , Yao Xie\",\"doi\":\"10.1016/j.gande.2022.10.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide that seriously threatens human health. Chronic infection of hepatitis virus B, C and D is closely related to the occurrence of HCC, about 80% HCC cases are caused by chronic viral hepatitis. Effective antiviral therapy can control liver inflammation, reduce the occurrence of HCC and reduce the recurrence of HCC after surgery treatment. In addition, during chemotherapy such as transarterial chemoembolization (TACE) or hepatic artery infusion chemotherapy (HAIC), targeted therapy and immunotherapy for HCC, antiviral therapy is also needed to prevent hepatitis virus reactivation. Therefore, antiviral therapy plays an important role in the prevention and treatment of HCC.</p></div>\",\"PeriodicalId\":100571,\"journal\":{\"name\":\"Gastroenterology & Endoscopy\",\"volume\":\"1 1\",\"pages\":\"Pages 5-10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterology & Endoscopy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949752322000012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology & Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949752322000012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

肝细胞癌（HCC）是世界范围内严重威胁人类健康的第三大癌症相关死亡原因。慢性乙型、丙型和丁型肝炎病毒感染与HCC的发生密切相关，约80%的HCC病例是由慢性病毒性肝炎引起的。有效的抗病毒治疗可以控制肝脏炎症，减少HCC的发生，减少手术治疗后HCC的复发。此外，在肝细胞癌的化疗过程中，如经动脉化疗栓塞（TACE）或肝动脉灌注化疗（HAIC）、靶向治疗和免疫治疗，还需要抗病毒治疗来防止肝炎病毒的再激活。因此，抗病毒治疗在HCC的预防和治疗中发挥着重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide that seriously threatens human health. Chronic infection of hepatitis virus B, C and D is closely related to the occurrence of HCC, about 80% HCC cases are caused by chronic viral hepatitis. Effective antiviral therapy can control liver inflammation, reduce the occurrence of HCC and reduce the recurrence of HCC after surgery treatment. In addition, during chemotherapy such as transarterial chemoembolization (TACE) or hepatic artery infusion chemotherapy (HAIC), targeted therapy and immunotherapy for HCC, antiviral therapy is also needed to prevent hepatitis virus reactivation. Therefore, antiviral therapy plays an important role in the prevention and treatment of HCC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊